Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment ...

Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in Australia. AK138D1, a self-developed and ...

GU ASCO annual meeting featured a session on the ABCs of antibody drug conjugates and a presentation by Dr. Di Maria Jiang discussing the targeting of bladder cancer with antibody drug conjugates. Dr.

Innovative Bispecific Antibody Therapies in Cancer Treatment Emerge as Patent Filings SurgeDublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibody & Cancer Patent Landscape Analysis" report ...

The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.

The study aims to compare the efficacy and safety of JSKN003 versus investigator-selected chemotherapy in this patient population. JSKN003 is an anti-HER2 bispecific antibody-drug conjugate (bis-ADC), ...

There is a commercial access agreement for olaparib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Mim8 is a factor VIIIa mimetic bispecific antibody that bridges factor IXa and factor X. This bridging replaces factor VIII, restoring thrombin production and clotting ability. The open-label ...

而HR阳性、HER2阴性乳腺癌是最常见的乳腺癌类型，占所有乳腺癌病例的约70%。尽管内分泌治疗是HR阳性乳腺癌的标准治疗方案，但其疗效往往有限，后续化疗的效果也不尽如人意。 与此同时，HER3靶向治疗也逐渐崭露头角。2024年欧洲肿瘤内科学会（ESMO）年会上 ...

JSKN003 is an anti-HER2 bispecific ADC developed inhouse with Alphamab's proprietary Glycan-specific conjugation platform. The antibody molecule KN026 is site-specifically modified via enzyme ...